 SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 GLOBE NEWSWIRE -- Imago BioSciences, Inc. Imago Nasdaq: IMGO, a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms MPNs and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022. 